Japan Looks To Update National Biotechnology Strategy
This article was originally published in PharmAsia News
The Japanese government has set up a team to update its 2002 biotechnology strategic outline. The team will discuss topics such as promoting research and development, early commercialization of new technology and raising public awareness. Regenerative medicine and medical devices are also included in the discussions. The team plans to release a midterm report in June. Led by Tasuku Honjo of the Council for Science and Technology, the team consists of researchers and industrial representatives, including Hatsuo Aoki, president of the Japan Pharmaceutical Manufacturers Association. At the first meeting, Minister of State for Science, Technology and Innovation Policy, Fumio Kishida, commented that an industry-government-academia alliance is vital for the advancement of Japan's biotechnology policy. (Click here for more-J apanese language
You may also be interested in...
Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.
Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.
Plaintiffs against the prestige, “clinical” skin-care company are targeting anti-aging claims on its Rose Stem Cell Bio-Repair line and statements about hyaluronic acid’s ultra-moisturizing capabilities, used to market its Water Drench range. PTR faces false advertising class actions in California and New York federal courts, and the former case appears to be headed for trial.